Skip to main content
. Author manuscript; available in PMC: 2022 Dec 28.
Published in final edited form as: Invest New Drugs. 2022 Oct 20;40(6):1306–1314. doi: 10.1007/s10637-022-01311-w

Table 5.

Best Overall Response

Response N %
Complete response 0 0.0
Partial response 0 0.0
Stable disease 8 66.7
Progression 2 16.7
Insufficient evaluationa 1 8.3
Unevaluableb 1 8.3
Total 12 100.0
a

Symptomatic deterioration reported but died prior to documented disease progression

b

Did not complete one cycle of treatment